3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Early Intervention, Educational
5
Radiotherapy
4
Psychiatric Rehabilitation
4
Capecitabine
4
pembrolizumab
3
Trastuzumab
3
Methods
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Gemcitabine
3
Counseling
3
trametinib
2
palbociclib
2
cediranib
2
Standard of Care
2
Mental Status and Dementia Tests
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cyclophosphamide
2
Biopsy
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
veliparib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
spartalizumab
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
nanocis
×
Breast
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled